Information Provided By: 
Fly News Breaks for August 7, 2019
REGN
Aug 7, 2019 | 08:49 EDT
Baird analyst Brian Skorney upgraded Regeneron to Outperform from Neutral as he thinks shares have overshot to the downside after the stock has "taken a beating" amid investor concerns about Part B reform, Eylea competition and frustration with management. He contends that Eylea is likely a long way from materially declining, Dupixent has "become a freight train of a drug launch" and the pipeline is starting to look more interesting. Skorney maintains a $410 price target on Regeneron shares.
News For REGN From the Last 2 Days
